Subcutaneous Trastuzumab for HER2-positive Breast Cancer – Evidence and Practical Experience in 7 German Centers

A subcutaneous formulation of trastuzumab to treat patients with HER2-positive breast cancer is available since August 2013. The subcutaneous formulation is administered as a fixed dose of 600 mg over a period of up to 5 minutes. The HannaH trial compared subcutaneous with intravenous administration...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Geburtshilfe Frauenheilkd
Hoofdauteurs: Jackisch, C., Müller, V., Dall, P., Neumeister, R., Park-Simon, T.-W., Ruf-Dördelmann, A., Seiler, S., Tesch, H., Ataseven, B.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Georg Thieme Verlag KG 2015
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4490923/
https://ncbi.nlm.nih.gov/pubmed/26166837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1055/s-0035-1546172
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items